HK1019233A1 - Animal cells and processes for the replication of influenza viruses - Google Patents

Animal cells and processes for the replication of influenza viruses

Info

Publication number
HK1019233A1
HK1019233A1 HK99104226.0A HK99104226A HK1019233A1 HK 1019233 A1 HK1019233 A1 HK 1019233A1 HK 99104226 A HK99104226 A HK 99104226A HK 1019233 A1 HK1019233 A1 HK 1019233A1
Authority
HK
Hong Kong
Prior art keywords
influenza viruses
replication
processes
animal cells
cells
Prior art date
Application number
HK99104226.0A
Other languages
English (en)
Inventor
Albrecht Groner
Jurgen Vorlop
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Publication of HK1019233A1 publication Critical patent/HK1019233A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HK99104226.0A 1996-04-01 1999-09-29 Animal cells and processes for the replication of influenza viruses HK1019233A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19612966A DE19612966B4 (de) 1996-04-01 1996-04-01 MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
PCT/IB1997/000403 WO1997037000A1 (en) 1996-04-01 1997-04-01 Animal cells and processes for the replication of influenza viruses

Publications (1)

Publication Number Publication Date
HK1019233A1 true HK1019233A1 (en) 2000-01-28

Family

ID=7790126

Family Applications (1)

Application Number Title Priority Date Filing Date
HK99104226.0A HK1019233A1 (en) 1996-04-01 1999-09-29 Animal cells and processes for the replication of influenza viruses

Country Status (10)

Country Link
US (4) US6455298B1 (hr)
EP (2) EP2275535A1 (hr)
JP (7) JP4243349B2 (hr)
AT (1) ATE482267T1 (hr)
DE (2) DE19612966B4 (hr)
DK (1) DK0904351T3 (hr)
ES (1) ES2352638T3 (hr)
HK (1) HK1019233A1 (hr)
PT (1) PT904351E (hr)
WO (1) WO1997037000A1 (hr)

Families Citing this family (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19612966B4 (de) * 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
DE19612967A1 (de) * 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
WO1999021967A1 (de) * 1997-10-25 1999-05-06 Roche Diagnostics Gmbh Suspensions-verpackungszellinien für retrovirusvektoren
SK285971B6 (sk) 1997-12-24 2007-12-06 Duphar International Research B. V. Spôsob prípravy buniek na výrobu biologických materiálov
US6825036B2 (en) 2000-03-03 2004-11-30 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell
JP3547715B2 (ja) * 2001-03-06 2004-07-28 榮 新垣 ベクター精製用装置及び方法
DE10144903A1 (de) * 2001-09-12 2003-03-27 Chiron Behring Gmbh & Co Vermehrung von Viren in Zellkultur
DE10144906B4 (de) 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
US20030078471A1 (en) * 2001-10-18 2003-04-24 Foley Frederick J. Manipulation of an organ
US6951752B2 (en) * 2001-12-10 2005-10-04 Bexter Healthcare S.A. Method for large scale production of virus antigen
CN103540568A (zh) 2002-04-26 2014-01-29 米迪缪尼有限公司 制备流感病毒的多质粒系统
US7465456B2 (en) 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
US20060110406A1 (en) * 2003-02-25 2006-05-25 Medimmune Vaccines, Inc. Refrigerator-temperature stable influenza vaccine compositions
AU2004263813B8 (en) 2003-02-25 2008-09-11 Medimmune, Llc Methods of producing influenza vaccine compositions
CA2503774C (en) * 2003-06-20 2007-09-25 Microbix Biosystems Inc. Improvements in virus production
WO2005026333A1 (ja) * 2003-09-09 2005-03-24 Japan Science And Technology Agency プロテアーゼを用いた接着性細胞の浮遊培養技術、及び該細胞を宿主として用いてウィルスを生産する方法
DE602004027537D1 (hr) 2003-12-23 2010-07-15 Medimmune Inc
JP5600375B2 (ja) 2004-03-09 2014-10-01 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド インフルエンザウイルスワクチン
EP1734993A4 (en) * 2004-04-01 2009-10-21 Alza Corp DEVICE AND METHOD FOR THE TRANSDERMAL DISTRIBUTION OF THE GRIP VACCINE
EP1747268A1 (en) * 2004-05-20 2007-01-31 ID Biomedical Corporation Process for the production of an influenza vaccine
RS51721B (en) 2004-09-09 2011-10-31 Novartis Vaccines And Diagnostics Gmbh. Reduction of potential iatrogenic risks associated with influenza vaccines
KR101376889B1 (ko) 2004-10-06 2014-03-25 메디뮨 엘엘씨 냉장 온도 안정성 인플루엔자 백신 조성물
DE102004049290A1 (de) * 2004-10-09 2006-04-20 Bayer Healthcare Ag Verfahren zur Herstellung von Virusmaterial
CN101076355A (zh) * 2004-11-03 2007-11-21 希龙公司 流感疫苗
ES2536745T3 (es) 2004-12-08 2015-05-28 Medimmune, Llc Métodos de producción de composiciones de vacuna contra la gripe
EP1831353B1 (en) * 2004-12-23 2012-02-29 MedImmune, LLC Non-tumorigenic mdck cell line for propagating viruses
US7572620B2 (en) 2005-01-11 2009-08-11 Wisconsin Alumni Research Foundation H3 equine influenza A virus
FR2884255B1 (fr) 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
US20070111309A1 (en) * 2005-10-04 2007-05-17 Daelli Marcelo G Vero cell line adapted to grow in suspension
PL1951296T5 (pl) 2005-11-01 2015-06-30 Seqirus Uk Ltd Szczepionki wirusowe otrzymane z komórek o niskim poziomie pozostałości DNA komórkowego poprzez traktowanie beta-propiolaktonem
US10842867B2 (en) 2005-11-04 2020-11-24 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
AU2006310163B2 (en) 2005-11-04 2011-09-15 Seqirus UK Limited Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
BRPI0618254A2 (pt) 2005-11-04 2011-08-23 Novartis Vaccines & Diagnostic emulsões com agente tensoativo de fase aquosa livre para fornecer adjuvante às vacinas contra influenza dividido
WO2007052056A1 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Adjuvanted influenza vaccines including cytokine-inducing agents
AU2006310339B2 (en) 2005-11-04 2013-01-10 Novartis Ag Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
NZ570106A (en) 2006-01-27 2012-04-27 Novartis Vaccines & Diagnostic Influenza vaccines containing hemagglutinin and matrix proteins
JP2009534303A (ja) * 2006-03-24 2009-09-24 ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー 冷蔵しないインフルエンザワクチンの保存
CA2647985C (en) 2006-03-31 2014-12-30 Warf-Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines
EP2022849A4 (en) * 2006-05-11 2010-10-06 Chemo Sero Therapeut Res Inst METHOD FOR PROLIFERATION OF INFLUENZA VIRUS
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
EP2497495B3 (en) * 2006-09-11 2021-02-17 Seqirus UK Limited Making influenza virus vaccines without using eggs
SG174813A1 (en) 2006-09-15 2011-10-28 Medimmune Llc Mdck cell lines supporting viral growth to high titers and bioreactor process using the same
PL2121011T3 (pl) 2006-12-06 2014-10-31 Novartis Ag Szczepionki zawierające antygeny czterech szczepów wirusa grypy
US9474798B2 (en) 2007-06-18 2016-10-25 Wisconsin Alumni Research Foundation Influenza M2 protein mutant viruses as live influenza attenuated vaccines
WO2008157583A1 (en) 2007-06-18 2008-12-24 Medimmune, Llc Influenza b viruses having alterations in the hemaglutinin polypeptide
ES2393162T3 (es) * 2007-06-27 2012-12-19 Novartis Ag Vacunas antigripales con un contenido reducido de aditivos
EP3327132A3 (en) * 2007-08-09 2018-07-18 Wyeth LLC Use of perfusion to enhance production of fed-batch cell culture in bioreactors
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
AU2008339631B2 (en) 2007-12-24 2014-07-24 Novartis Ag Assays for adsorbed influenza vaccines
US8506966B2 (en) 2008-02-22 2013-08-13 Novartis Ag Adjuvanted influenza vaccines for pediatric use
CA2718430A1 (en) 2008-03-18 2009-09-24 Novartis Ag Improvements in preparation of influenza virus vaccine antigens
TW201012930A (en) 2008-06-16 2010-04-01 Intervet Int Bv Method of replicating viruses in suspension
MY172788A (en) 2008-08-01 2019-12-12 Gamma Vaccines Pty Ltd Influenza vaccines
AU2009296701B2 (en) 2008-09-24 2015-02-19 Medimmune, Llc Methods for cultivating cells, propagating and purifying viruses
KR20110074563A (ko) 2008-09-24 2011-06-30 메디뮨 엘엘씨 바이러스의 정제 방법
WO2010079081A1 (en) 2009-01-07 2010-07-15 Glaxosmithkline Biologicals S.A. Methods for recovering a virus or a viral antigen produced by cell culture
WO2010089339A1 (en) 2009-02-06 2010-08-12 Glaxosmithkline Biologicals S.A. Purification of virus or viral antigens by density gradient ultracentrifugation
EP2396031A1 (en) 2009-02-10 2011-12-21 Novartis AG Influenza vaccines with increased amounts of h3 antigen
AU2010212547B2 (en) 2009-02-10 2015-03-12 Seqirus UK Limited Influenza vaccine regimens for pandemic-associated strains
EP3173097A3 (en) 2009-02-10 2017-07-12 Seqirus UK Limited Influenza vaccines with reduced amounts of squalene
EP2424565A1 (en) 2009-04-27 2012-03-07 Novartis AG Adjuvanted vaccines for protecting against influenza
WO2010128396A2 (en) 2009-05-08 2010-11-11 Novartis Ag Generic assays for detection of influenza viruses
PT2401384E (pt) 2009-05-21 2012-12-19 Novartis Ag Genética reversa com recurso a promotores da pol i não endógenos
WO2010136896A1 (en) 2009-05-29 2010-12-02 Novartis Ag Assays for influenza virus hemagglutinins
AU2010277310B2 (en) 2009-07-31 2015-01-15 Seqirus UK Limited Reverse genetics systems
WO2011030218A1 (en) 2009-09-10 2011-03-17 Novartis Ag Combination vaccines against respiratory tract diseases
PL2491117T3 (pl) 2009-10-20 2014-05-30 Novartis Ag Udoskonalone sposoby odzyskiwania wirusa wykorzystujące odwrotną genetykę
JP2013507990A (ja) 2009-10-26 2013-03-07 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション ベロ細胞において増強された複製を有する高力価の組換えインフルエンザウイルス
DE102009056883B4 (de) 2009-12-03 2012-08-16 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
DE102009056884B4 (de) 2009-12-03 2021-03-18 Novartis Ag Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
EP2506833B1 (en) 2009-12-03 2014-04-16 Novartis AG Arranging interaction and back pressure chambers for microfluidization
SI2356983T1 (sl) 2009-12-03 2013-05-31 Novartis Ag KroĹľenje komponent med homogenizacijo emulzij
DE102009056871A1 (de) 2009-12-03 2011-06-22 Novartis AG, 4056 Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
EP2343052B1 (en) 2009-12-03 2013-06-12 Novartis AG Hydrophilic filtration during manufacture of vaccine adjuvants
WO2011095596A1 (en) 2010-02-04 2011-08-11 Vivalis Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells
WO2011110955A2 (en) 2010-03-08 2011-09-15 Novartis Ag Methods of testing for intracellular pathogens
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
CN102858961A (zh) 2010-05-03 2013-01-02 葛兰素史密丝克莱恩生物有限公司 新方法
EP2566323A2 (en) 2010-05-06 2013-03-13 Novartis AG Organic peroxide compounds for microorganism inactivation
ES2597158T5 (es) 2010-05-12 2020-03-26 Novartis Ag Procedimientos mejorados para preparar escualeno
JP5876036B2 (ja) 2010-05-21 2016-03-02 ノバルティス アーゲー インフルエンザウイルス再集合方法
WO2011151726A2 (en) 2010-06-01 2011-12-08 Novartis Ag Concentration of vaccine antigens with lyophilization
KR102113512B1 (ko) 2010-06-01 2020-05-22 노파르티스 아게 동결건조하지 않는 인플루엔자 백신 항원의 농축
WO2012041311A1 (de) * 2010-08-16 2012-04-05 Cevec Pharmaceuticals Gmbh Permanente humane amniozyten zelllinie zur herstellung von influenzaviren
US9051361B2 (en) 2010-08-17 2015-06-09 National Health Research Institutes Immunogenic compositions and uses thereof
EP2605792B1 (en) 2010-08-20 2014-12-10 Novartis AG Soluble needle arrays for delivery of influenza vaccines
EP2614163B1 (en) 2010-09-07 2016-01-06 Novartis AG Generic assays for detection of mammalian reovirus
CA2825403C (en) 2011-01-27 2023-02-21 Gamma Vaccines Pty Limited Vaccines comprising a combination of gamma irradiated influenza virus and a further immunogen
ES2572391T3 (es) 2011-02-25 2016-05-31 Novartis Ag Control exógeno interno positivo para la detección de virus
GB201216121D0 (en) 2012-09-10 2012-10-24 Novartis Ag Sample quantification by disc centrifugation
JP2014532620A (ja) 2011-10-20 2014-12-08 ノバルティス アーゲー 小児の初回免疫のためのアジュバント添加インフルエンザｂウイルスワクチン
EP3023790A1 (en) 2011-12-12 2016-05-25 Novartis AG Assay for influenza virus hemagglutinins
AU2014203051C1 (en) * 2012-03-02 2016-09-01 Seqirus UK Limited Influenza Virus Reassortment
JP6054883B2 (ja) 2012-03-02 2016-12-27 ノバルティス アーゲー インフルエンザウイルスの再集合
EP2822585B1 (en) 2012-03-06 2017-05-17 Janssen Vaccines & Prevention B.V. Improved vaccination against influenza
JP6152535B2 (ja) * 2012-04-16 2017-06-28 公益財団法人ヒューマンサイエンス振興財団 細胞培養組成物及びインフルエンザウイルスの生産方法
CA2875752A1 (en) 2012-06-04 2013-12-12 Novartis Ag Improved safety testing
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
CN105120893B (zh) 2012-12-03 2018-11-13 诺华股份有限公司 流感病毒重配
JP6525469B2 (ja) 2013-03-13 2019-06-05 ノバルティス アーゲー インフルエンザｂ型ウイルス再集合
MX2015015428A (es) 2013-05-10 2016-07-18 Novartis Ag Eliminacion de riesgo de narcolepsia en vacunas contra influenza.
DE202013005130U1 (de) 2013-06-05 2013-09-10 Novartis Ag Influenza Virus Reassortierung
DE202013005100U1 (de) 2013-06-05 2013-08-26 Novartis Ag Influenza Virus Reassortierung
CN105722976A (zh) 2013-06-06 2016-06-29 诺华股份有限公司 流感病毒重配
KR101370512B1 (ko) 2013-06-07 2014-03-06 재단법인 목암생명공학연구소 무단백 배지에서 부유 배양되는 mdck 유래 세포주 및 상기 세포주를 이용하여 바이러스를 증식시키는 방법
AU2014290203B2 (en) 2013-07-15 2020-12-24 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in MDCK or vero cells or eggs
ES2778928T3 (es) 2013-08-30 2020-08-12 Glaxosmithkline Biologicals Sa Producción a gran escala de virus en cultivos celulares
US20160287693A1 (en) 2013-11-15 2016-10-06 Novartis Ag Removal of residual cell culture impurities
TWI743024B (zh) 2014-06-06 2021-10-21 美商健臻公司 灌注培養方法及其用途
TWI776235B (zh) * 2014-06-09 2022-09-01 美商健臻公司 種子罐培養法(seed train processes)及其用途
WO2015196150A2 (en) 2014-06-20 2015-12-23 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
AU2015252119A1 (en) 2014-11-07 2016-05-26 Takeda Vaccines, Inc. Hand, foot, and mouth vaccines and methods of manufacture and use thereof
AR102547A1 (es) 2014-11-07 2017-03-08 Takeda Vaccines Inc Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
EP3226904B1 (en) 2014-12-02 2019-03-06 Novartis AG Manufacture of surfactant-containing compositions
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
EP3313439A2 (en) 2015-06-26 2018-05-02 Seqirus UK Limited Antigenically matched influenza vaccines
WO2017007839A1 (en) 2015-07-06 2017-01-12 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
KR20230132628A (ko) 2015-07-07 2023-09-15 세퀴러스 유케이 리미티드 인플루엔자 효능 검정
TWI781915B (zh) 2015-10-30 2022-11-01 財團法人國家衛生研究院 用於疫苗製備之於無血清、化學性界定培養基中之mdck懸浮細胞株
CN109477074B (zh) 2016-02-19 2023-01-24 威斯康星旧生研究基金会 用于疫苗开发的改进的乙型流感病毒复制
US20190078056A1 (en) 2016-03-29 2019-03-14 The Research Foundation For Microbial Diseases Of Osaka University Method for culturing mdck cells
JP2017038622A (ja) * 2016-11-21 2017-02-23 ウィスコンシン アルムニ リサーチ ファンデイション Ｈ３型ウマａ型インフルエンザウイルス
JP2021502350A (ja) 2017-11-03 2021-01-28 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. ジカワクチン及び免疫原性組成物、ならびにその使用方法
WO2020167432A2 (en) 2019-01-23 2020-08-20 Yoshihiro Kawaoka Mutations that confer genetic stability to additional genes in influenza viruses
JP2022522112A (ja) 2019-02-08 2022-04-14 ウィスコンシン アルムニ リサーチ ファンデイション ヒト化細胞系
WO2020223699A1 (en) 2019-05-01 2020-11-05 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
CN113939311A (zh) 2019-05-08 2022-01-14 武田疫苗股份有限公司 灭活病毒组合物和寨卡疫苗制剂
EP4022046A2 (en) 2019-08-27 2022-07-06 Wisconsin Alumni Research Foundation (WARF) Recombinant influenza viruses with stabilized ha for replication in eggs
KR20220128613A (ko) 2019-11-18 2022-09-21 세퀴러스 피티와이 리미티드 재배열 인플루엔자 바이러스의 제조 방법
JP2023532944A (ja) 2020-06-30 2023-08-01 セキラス ユーケー リミテッド 水中油型エマルジョンアジュバントの低温濾過
WO2023154043A1 (en) 2022-02-09 2023-08-17 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1278075B (de) * 1964-06-22 1968-09-19 Norden Lab Inc Verwendung von Gewebekulturen zur Zuechtung von Viren fuer die Gewinnung von Impfstoffen
US3616203A (en) * 1969-12-11 1971-10-26 Norden Lab Inc Virus culture and method
US4064232A (en) 1974-01-14 1977-12-20 Sandoz Ltd. Process for isolating the immunogenic components of influenza viruses
CA1122527A (en) 1979-05-15 1982-04-27 Karen K. Brown Influenza vaccine production in liquid cell culture
US4500513A (en) * 1979-05-15 1985-02-19 Miles Laboratories, Inc. Influenza vaccine production in liquid cell culture
USRE33164E (en) * 1979-05-15 1990-02-13 Mobay Corporation Influenza vaccine production in liquid cell culture
US5013663A (en) * 1983-06-15 1991-05-07 American Home Products Corporation Canine corona virus vaccine
US4783411A (en) 1984-10-22 1988-11-08 Janis Gabliks Influenza-A virus vaccine from fish cell cultures
DE69024392T2 (de) 1989-03-29 1996-07-25 Univ New York Verfahren zur Reinigungbvon Aussenmembran-Protein von Haemophilus influenzae
JP2827298B2 (ja) * 1989-07-10 1998-11-25 三菱化学株式会社 細胞培養担体
AT393277B (de) 1990-01-04 1991-09-25 Immuno Ag Verfahren zur herstellung von fruehsommer- meningoenzephalitis-virus (fsme-virus)-antigen
JPH0420284A (ja) * 1990-05-12 1992-01-23 Mitsubishi Kasei Corp 細胞培養用マイクロキャリア
JPH05207873A (ja) * 1992-01-27 1993-08-20 Mitsubishi Kasei Corp 付着性動物細胞の培養方法
US5762939A (en) * 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
US5756341A (en) * 1994-11-10 1998-05-26 Immuno Ag Method for controlling the infectivity of viruses
US5753489A (en) * 1994-11-10 1998-05-19 Immuno Ag Method for producing viruses and vaccines in serum-free culture
CA2415990C (en) 1994-11-10 2009-07-07 Immuno Aktiengesellschaft Method for producing biologicals in protein-free culture
WO1996015232A1 (en) 1994-11-16 1996-05-23 St. Jude Children's Research Hospital Novel replication process
US5646033A (en) * 1994-11-30 1997-07-08 Dyncorp African green monkey kidney cell lines useful for maintaining viruses and for preparation of viral vaccines
CA2232515A1 (en) 1995-09-22 1997-03-27 Connaught Laboratories Limited Parainfluenza virus glycoproteins and vaccines
DE19612967A1 (de) 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
DE19612966B4 (de) * 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
US6514502B1 (en) * 1999-01-26 2003-02-04 Schering-Plough Veterinary Corporation Propagation of bovine cononavirus in chinese hamster ovary cells

Also Published As

Publication number Publication date
JP2005211080A (ja) 2005-08-11
EP0904351B1 (en) 2010-09-22
WO1997037000A1 (en) 1997-10-09
DE19612966A1 (de) 1997-10-02
DK0904351T3 (da) 2010-11-01
PT904351E (pt) 2010-12-28
DE69740002D1 (de) 2010-11-04
EP2275535A1 (en) 2011-01-19
US20050202553A1 (en) 2005-09-15
EP0904351A1 (en) 1999-03-31
JP2004331673A (ja) 2004-11-25
JP2009034115A (ja) 2009-02-19
JP2006230415A (ja) 2006-09-07
US20030073223A1 (en) 2003-04-17
JP4243349B2 (ja) 2009-03-25
DE19612966B4 (de) 2009-12-10
US20080274141A1 (en) 2008-11-06
JP2012005502A (ja) 2012-01-12
US6656720B2 (en) 2003-12-02
JP2000507448A (ja) 2000-06-20
ATE482267T1 (de) 2010-10-15
US6455298B1 (en) 2002-09-24
JP2012016358A (ja) 2012-01-26
ES2352638T3 (es) 2011-02-22

Similar Documents

Publication Publication Date Title
HK1019233A1 (en) Animal cells and processes for the replication of influenza viruses
HK1142093A1 (en) Process for the replication of influenza viruses in cell culture, and the influenza viruses obtainable by the process
UA42089C2 (uk) Протигрипозна вакцина на основі поверхневого антигену, спосіб її виробництва
ATE399855T1 (de) Tierzellkulturmedium mit pflanzlichen nährstoffen
EA200200604A1 (ru) Производство вакцин
IL192762A0 (en) Method for identifying cell differentiation factors
DK0500917T3 (da) Vacciner og fremgangsmåder baseret på rekombinante herpes simplex virusser.
BRPI0407636A (pt) meio de cultura de células, linhagem de células animais, métodos para produzir um meio de cultura condicionado, células animais, uma cultura de células animais, vìrus em uma cultura de células animais, ou, de preferência, humanas diplóides dependentes de ancoragem, método para produzir uma vacina, e, população de vìrus
DK1155116T3 (da) Anvendelse af kollagenase i fremstillingen af kulturer af neurale stamceller
DE69626022D1 (de) Verfahren zur industriellen herstellung eines japanischen enkephalitis impfstoffes, und so erhaltener impfstoff
EP1077599A4 (en) BRASSICA TRANSFORMATION BY PARTICLE Bombardment
ES8104405A1 (es) Procedimiento para preparar una vacuna de virus de gripe
HU9202009D0 (en) Matrix with adherently bound cells and method for producing viruses and antigens thereof
WO1998036636A3 (en) Method for generating embryogenic cell cultures for the production of bananas (musa spp.)
CA2250714A1 (en) Animal cells and processes for the replication of influenza viruses
AU583795B2 (en) Process for the maintenance and proliferation of virus genomes and derivatives thereof
ES2052883T3 (es) Cultivo de celulas de riñon de cerdo y su uso en la produccion de vacunas.
AU584774B2 (en) Process for regenerating corn
DK1238057T3 (da) Fremgangsmåde til produktion af vedhæftende dyreceller
AU6262786A (en) Growing aids virus in cell lines lacking human class ii histocompatability antigens
BRPI0002694C1 (pt) processo de obtenção de vacina contra raiva em células vero, para uso humano
JPS5765184A (en) Stable immobilized adenylate kinase composite and its preparation

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20170331